U.S. market Closed. Opens in 7 hours 40 minutes

CARA | Cara Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.2824 - 0.2996
52 Week Range 0.2400 - 1.4000
Beta 0.60
Implied Volatility 587.17%
IV Rank 72.95%
Day's Volume 286,012
Average Volume 379,301
Shares Outstanding 54,846,600
Market Cap 16,004,238
Sector Healthcare
Industry Biotechnology
IPO Date 2014-01-31
Valuation
Profitability
Growth
Health
P/E Ratio -0.14
Forward P/E Ratio N/A
EPS -2.04
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 55
Country USA
Website CARA
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
CARA's peers: ZYNE, XXII, CRBP, CBDS, CANN
*Chart delayed
Analyzing fundamentals for CARA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see CARA Fundamentals page.

Watching at CARA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CARA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙